What does Pharmaconsult do?

Pharmaconsult is a pharmacy in Beringen. Private Limited, started on 19 December 2012, 1 establishment.

What is the address of Pharmaconsult?

The registered office of Pharmaconsult is located at Heerbaan 232, 3582 Beringen.

Is Pharmaconsult still active?

Yes. According to the CBE (30 October 2026) Pharmaconsult is active, legal situation “Normale toestand”, started on 19 December 2012.

Is Pharmaconsult registered on Peppol?

Yes, Pharmaconsult is registered on the Peppol network with ID 0208:0508581589.

What is the enterprise number of Pharmaconsult?

The enterprise number of Pharmaconsult is BE0508581589.

When was Pharmaconsult founded?

Pharmaconsult was founded on 19 December 2012.

Who are the directors of Pharmaconsult?

According to the 2025 annual accounts, the directors of Pharmaconsult are: Pharmatopia NV NV.

Is Pharmaconsult a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 December 2012; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Pharmaconsult make in 2025?

Pharmaconsult posted a profit after taxes of € 5,843 in financial year 2025.

What is the revenue of Pharmaconsult?

As a small company, Pharmaconsult is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 75,930.

How much does an employee at Pharmaconsult earn?

The average wage cost per full-time employee at Pharmaconsult was € 6,600 in 2024: staff costs of € 6,557 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Pharmaconsult have?

According to the 2025 annual accounts, Pharmaconsult has 0 full-time equivalents (FTE).

Pharmaconsult (Private Limited) - Beringen - BE0508581589

Dossier Pharmaconsult, printed on 30 October 2026 from databakkes.be/en/0508581589/pharmaconsult. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Pharmaconsult from Beringen, company number BE0508581589, closed financial year 2025 with a result of € 5,843 after tax. For that financial year Pharmaconsult recorded a gross margin of € 75,930 and equity of € 286,815. Compared with financial year 2024, the result moved from € 2,185 to € 5,843. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on March 23, 2026.

What it is worth Growing

€ 286,815

▲ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 5,843

▲ 167% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 156,614

▲ 24% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 266,355.

People and assets in 2025

Full-time equivalents

▼ 1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 86

▼ 99% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 2,246

▼ 22% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 163,273

▼ 17% vs 2024

€ 36,919 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 217,366

▲ 14% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 26

▼ 50% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 231,267 Gross margin 2022: € 231,267 First fiscal year in the series	€ 163,165 Gross margin 2023: € 163,165 ▼ 29% vs 2022 (€ 231,267) Unfavourable step	€ 79,763 Gross margin 2024: € 79,763 ▼ 51% vs 2023 (€ 163,165) Unfavourable step	€ 75,930 Gross margin 2025: € 75,930 ▼ 5% vs 2024 (€ 79,763) Unfavourable step	▼ 5%
Profit after taxes	€ 61,591 Profit after taxes 2022: € 61,591 First fiscal year in the series	€ 35,828 Profit after taxes 2023: € 35,828 ▼ 42% vs 2022 (€ 61,591) Unfavourable step	€ 2,185 Profit after taxes 2024: € 2,185 ▼ 94% vs 2023 (€ 35,828) Unfavourable step	€ 5,843 Profit after taxes 2025: € 5,843 ▲ 167% vs 2024 (€ 2,185) Favourable step	▲ 167%
Equity	€ 242,959 Equity 2022: € 242,959 First fiscal year in the series	€ 278,787 Equity 2023: € 278,787 ▲ 15% vs 2022 (€ 242,959) Favourable step	€ 280,972 Equity 2024: € 280,972 ▲ 1% vs 2023 (€ 278,787) Favourable step	€ 286,815 Equity 2025: € 286,815 ▲ 2% vs 2024 (€ 280,972) Favourable step	▲ 2%
Total debts	€ 438,269 Total debts 2022: € 438,269 First fiscal year in the series	€ 376,178 Total debts 2023: € 376,178 ▼ 14% vs 2022 (€ 438,269) Favourable step	€ 389,886 Total debts 2024: € 389,886 ▲ 4% vs 2023 (€ 376,178) Unfavourable step	€ 382,954 Total debts 2025: € 382,954 ▼ 2% vs 2024 (€ 389,886) Favourable step	▼ 2%
Cash	€ 97,938 Cash 2022: € 97,938 First fiscal year in the series	€ 102,429 Cash 2023: € 102,429 ▲ 5% vs 2022 (€ 97,938) Favourable step	€ 125,849 Cash 2024: € 125,849 ▲ 23% vs 2023 (€ 102,429) Favourable step	€ 156,614 Cash 2025: € 156,614 ▲ 24% vs 2024 (€ 125,849) Favourable step	▲ 24%
Retained profit	€ 222,499 Retained profit 2022: € 222,499 First fiscal year in the series	€ 258,327 Retained profit 2023: € 258,327 ▲ 16% vs 2022 (€ 222,499) Favourable step	€ 260,512 Retained profit 2024: € 260,512 ▲ 1% vs 2023 (€ 258,327) Favourable step	€ 266,355 Retained profit 2025: € 266,355 ▲ 2% vs 2024 (€ 260,512) Favourable step	▲ 2%
Dividend	€ 25,000 Dividend 2022: € 25,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 25,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 318,043 Bank debt 2022: € 318,043 First fiscal year in the series	€ 236,940 Bank debt 2023: € 236,940 ▼ 26% vs 2022 (€ 318,043) Favourable step	€ 196,969 Bank debt 2024: € 196,969 ▼ 17% vs 2023 (€ 236,940) Favourable step	€ 163,273 Bank debt 2025: € 163,273 ▼ 17% vs 2024 (€ 196,969) Favourable step	▼ 17%
Balance sheet total	€ 681,228 Balance sheet total 2022: € 681,228 First fiscal year in the series	€ 654,965 Balance sheet total 2023: € 654,965 ▼ 4% vs 2022 (€ 681,228) Unchanged	€ 670,858 Balance sheet total 2024: € 670,858 ▲ 2% vs 2023 (€ 654,965) Unchanged	€ 669,769 Balance sheet total 2025: € 669,769 Unchanged (€ 670,858) Unchanged
Employees (FTE)	1.7 Employees (FTE) 2022: 1.7 First fiscal year in the series	1 Employees (FTE) 2023: 1 ▼ 0.7 vs 2022 (1.7) Unchanged	1 Employees (FTE) 2024: 1 Unchanged (1) Unchanged	0 Employees (FTE) 2025: 0 ▼ 1 vs 2024 (1) Unchanged	▼ 1

Key figures of Pharmaconsult, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to Pharmaconsult?

What happened at Pharmaconsult in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Mar 23, 2026 New annual accounts for financial year 2025: profit of € 5,843 (▲ 167% vs 2024). Source: NBB ↗
2023 Pharmatopia NV NV became a director. NBB
Dec 19, 2012 New establishment in Beringen. KBO
Dec 19, 2012 Start of the company according to the CBE. KBO

In short

From € 61,591 profit in 2022 to € 5,843 profit in 2025.

Paid € 37,364 in corporate taxes since 2022.

Best year ever: 2022, with € 61,591 profit.

On average € 79,800 of value added per employee in 2024.

Original PDFs at the National Bank ↗

Management

PHARMATOPIA 100%

The stake of PHARMATOPIA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Pharmaconsult

Behind Pharmaconsult is Pharmatopia NV NV. The shares are held by PHARMATOPIA (100%).

Directors

According to the 2025 annual accounts

Pharmatopia NV NV

Director · represented by Verbeeck Barbara

Also active at: Apoteek Van Bulck

since 2023

Shareholders

PHARMATOPIA

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Heerbaan 232

3582 Beringen

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

PHARMATOPIA same network

€ 606,286 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0508.581.589
VAT number: BE 0508.581.589
Registered office: Heerbaan 232, 3582 Beringen
Names & denominations: Pharmaconsult
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 19 December 2012
Peppol: Active · Active since 24 Nov 2023
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗